Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 15, 2019 - Issue
Submit an article Journal homepage
85
Views
3
CrossRef citations to date
0
Altmetric
Review

SGLT2 inhibitors and the changing landscape for treatment of diabetes

Shuangbo Liu1 Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
,
Anna Lam2 Division of Endocrinology, University of Alberta, Edmonton, Alberta, Canada
,
Arslan Wazir1 Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada
&
Asim N Cheema1 Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaCorrespondence[email protected]
Pages 861-867 | Published online: 09 Jul 2019

References

  • Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:1929–1949. doi:10.1016/j.jacc.2014.07.01725077860
  • International Diabetes Federation IDF Diabetes Atlas, 8th edn. Brussels, Belgium: International Diabetes Federation, 2017. Available from: http://www.diabetesatlas.org. Accessed December 1, 2018.
  • Public Health Agency of Canada, Diabetes in Canada: Facts and figures from a public health perspective. Ottawa, 2011 Available from: https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/cd-mc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/pdf/facts-figures-faits-chiffres-eng.pdf. Accessed December 1, 2018.
  • Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–828. doi:10.1056/NEJMoa100652421366473
  • Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–2572. doi:10.1056/NEJMoa080298718539916
  • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet (London, England). 1998;352:837–853.
  • The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968–983.7622004
  • Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med. 2008;358:2545–2559. doi:10.1056/NEJMoa080274318539917
  • Lipscombe L, Booth G, Butalia S, et al. Pharmacologic glycemic management of Type 2 diabetes in adults. Can J Diabetes. 2018;42(Suppl 1):S88–s103. doi:10.1016/j.jcjd.2017.10.03429650116
  • Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic Med. 2010;27:136–142. doi:10.1111/j.1464-5491.2009.02894.x20546255
  • Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol. 2001;280:F10–8. doi:10.1152/ajprenal.2001.280.1.F1011133510
  • Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117–2128. doi:10.1056/NEJMoa150472026378978
  • Lin B, Koibuchi N, Hasegawa Y, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148. doi:10.1186/1475-2840-13-8025344694
  • Habibi J, Aroor AR, Sowers JR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9. doi:10.1186/s12933-017-0624-528086951
  • Hammoudi N, Jeong D, Singh R, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of Type 2 diabetes. Cardiovasc Drug Ther. 2017;31:233–246. doi:10.1007/s10557-017-6734-1
  • Verma S, Mazer CDYan AT et al. Empa-heart cardiolink-6 trial: a randomized trial evaluating the effect of empagliflozin on left ventricular structure, function and biomarkers in people with type 2 diabetes (t2d) and coronary heart disease. Circulation. 2018;138:e751–e782.30566010
  • Verma S, Rawat S, Ho KL, et al. Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC. 2018;3:575–587. doi:10.1016/j.jacbts.2018.07.00630456329
  • Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in Type 2 diabetes. N Engl J Med. 2017;377:644–657. doi:10.1056/NEJMoa161192528605608
  • Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in Type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
  • Alfayez OM, Al Yami MS, Alshibani M, et al. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. Prim Care Diabetes. 2019;13:204–211. doi:10.1016/j.pcd.2019.01.00330713085
  • Singh AK, Singh R. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies. Expert Rev Clin Pharmacol. 2019;12:299–308. doi:10.1080/17512433.2019.158811030817235

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.